

REVIEW ARTICLE

The Chemical Composition and Biological Activity of Clove Essential Oil, *Eugenia caryophyllata* (*Syzygium aromaticum* L. Myrtaceae): A Short Review

Kamel Chaieb^{1*}, Hafedh Hajlaoui¹, Tarek Zmantar¹, Amel Ben Kahla-Nakbi¹, Mahmoud Rouabhia², Kacem Mahdouani³ and Amina Bakhrouf¹

¹Laboratoire d'Analyses, Traitement et Valorisation des Polluants de l'Environnement et des Produits, Faculté de Pharmacie, rue Avicenne 5000 Monastir, Tunisie

²Groupe de Recherche en Écologie Buccale, Faculté de Médecine Dentaire, Université Laval, Québec, QC, Canada

³Laboratoire de Bactériologie, Hôpital Régionale de Kairouan, Tunisie

The essential oil extracted from the dried flower buds of clove, *Eugenia caryophyllata* L. Merr. & Perry (Myrtaceae), is used as a topical application to relieve pain and to promote healing and also finds use in the fragrance and flavouring industries. The main constituents of the essential oil are phenylpropanoids such as carvacrol, thymol, eugenol and cinnamaldehyde. The biological activity of *Eugenia caryophyllata* has been investigated on several microorganisms and parasites, including pathogenic bacteria, *Herpes simplex* and hepatitis C viruses. In addition to its antimicrobial, antioxidant, antifungal and antiviral activity, clove essential oil possesses antiinflammatory, cytotoxic, insect repellent and anaesthetic properties. This short review addresses the chemical composition and biological effects of clove essential oil, and includes new results from GC/MS analysis and a study of its antimicrobial activity against a large number of multi-resistant *Staphylococcus epidermidis* isolated from dialysis biomaterials. Copyright © 2007 John Wiley & Sons, Ltd.

Keywords: *Eugenia caryophyllata*; clove essential oil; GC/MS; antimicrobial activity; *Staphylococcus epidermidis*; biological effect.

INTRODUCTION

The essential oil isolated from the buds of *Eugenia caryophyllata* L. Merr. & Perry (Myrtaceae) is widely used and well known for its medicinal properties. Traditional uses of clove oil include use in dental care, as an antiseptic and analgesic, where the undiluted oil may be rubbed on the gums to treat toothache. It is active against oral bacteria associated with dental caries and periodontal disease (Cai and Wu, 1996) and effective against a large number of other bacteria: *Escherichia coli*, *Listeria monocytogenes*, *Salmonella enterica* (Friedman *et al.*, 2002), *Campylobacter jejuni*, *Salmonella enteritidis*, *Escherichia coli* and *Staphylococcus aureus* (Beuchat, 2000; Cressy *et al.*, 2003; Kalemba and Kunicka, 2003). Previous studies have reported antifungal (Chami *et al.*, 2005), anticarcinogenic (Zheng *et al.*, 1992), antiallergic (Kim *et al.*, 1998) and antimutagenic activity (Miyazawa and Hisama, 2001). Eugenol, the primary component of clove oil displays antioxidant (Ogata *et al.*, 2000) and insecticidal (Park *et al.*, 2000) properties.

This is a review of the medicinal use of clove oil, and in order to further clarify the spectrum of antimicrobial

activity and its relation to chemical composition, its constitution was examined using GC/MS analysis. This characterized oil was subjected to antimicrobial testing against a large number of multi-resistant *Staphylococcus epidermidis* isolated from dialysis biomaterials. Coagulase-negative Staphylococci (CoNS) are a part of the normal skin microflora and are the most frequently isolated bacteria in hospitals (Agvald-Ohman *et al.*, 2003). These species have the ability to survive a long time on medical devices (Neely and Maley, 2000). Although CoNS do possess some intrinsic pathogenic properties, they are usually regarded as opportunistic agents (Huebner and Goldmann, 1999). The poor health status of dialysed patients renders them particularly vulnerable.

CHEMICAL COMPOSITION OF CLOVE ESSENTIAL OIL

The major component of clove oil is usually considered to be eugenol, with β -caryophyllene and lesser amounts of other components such as benzyl alcohol, but the proportions vary widely. For example, Prashar *et al.* (2006) found the content of eugenol to be 78%, with 13% β -caryophyllene, whereas Pawar and Thaker (2006) found that the content of eugenol was 47.64%, with the concentration of benzyl alcohol at 34.10%. We have characterized the composition of a sample of clove

* Correspondence to: Kamel Chaieb, Laboratoire d'Analyses, Traitement et Valorisation des Polluants de l'Environnement et des Produits, Faculté de Pharmacie, rue Avicenne 5000 Monastir, Tunisie.
E-mail: chaieb_mo@yahoo.fr

Table 1. Composition and percentage of clove essential oil (*Eugenia caryophyllata*) obtained with GS-MS analysis

N°	Compound ^{a,b}	Kovats index ^c (HP-20M)	Percentage (%)
1	2-Heptanone	1172	0.93232
2	Ethyl hexanoate	1232	0.66098
3	2-Heptanol	1304	tr
4	Menthyl octanoate	1384	tr
5	2-Nonanone	1392	tr
6	Ethyl octanoate	1429	tr
7	α -Cubebene	1459	tr
8	Copaene	1491	tr
9	2-Nonanol	1499	tr
10	Linalool	1548	tr
11	2-Undecanone	1588	tr
12	β -Caryophyllene	1595	1.38830
13	Menthyl benzoate	1619	tr
14	Ethyl benzoate	1647	tr
15	α -Humulene	1668	0.19985
16	Menthyl chavicol	1669	tr
17	α -Amorphene	1675	tr
18	α -Terpinyl acetate	1695	tr
19	α -Muurolene	1711	tr
20	Benzyl acetate	1714	tr
21	Carvone	1731	tr
22	γ -Cadinene	1756	tr
23	2-Phenyethyl acetate	1826	tr
24	(E)-Anethole	1827	tr
25	Calamenene	1828	0.10538
26	Benzyl alcohol	1861	tr
27	Calacorene	1918	0.11437
28	Caryophyllene oxide	1976	tr
29	Menthyl eugenol	1985	tr
30	Humulene oxide	1986	tr
31	Cinnamic aldehyde	2018	tr
32	Ethyl cinnamate	2072	tr
33	Benzyl tiglate	2103	tr
34	Eugenol	2151	88.58535
35	Eugenyl acetate	2263	5.62086
36	Humulenol	2265	0.27527
Total identified		98.2769	98.2769

^a Order of elution on HP-20M capillary.

^b Identified by comparison of the mass spectral and Kovats index data.

^c Kovats indices on HP-20M column, tr: trace (<0.1%).

essential oil isolated by hydro-distillation using GC-MS analysis. As shown in Table 1, the chemical analysis resulted in the identification of 36 components, with a high concentration of eugenol (88.58%), eugenyl acetate (5.62%), β -caryophyllene (1.39%), 2-heptanone (0.93%), ethyl hexanoate (0.66%), humulenol (0.27%), α -humulene (0.19%), calacorene (0.11%) and calamenene (0.10%). These data are in agreement with the results from other studies whilst still demonstrating the variability of the natural oil (Prashar *et al.*, 2006; Pawar and Thaker, 2006; Lee and Shibamoto, 2002).

IN VITRO STUDIES

Antibacterial activity of clove essential oil

The antibacterial activity of different *E. caryophyllata* extracts has been demonstrated against pathogenic bacteria including *Campylobacter jejuni*, *Salmonella enteritidis*, *Escherichia coli* and *Staphylococcus aureus* (Burt and Reinders, 2003; Feres *et al.*, 2005; Larhsini

et al., 2001; Cressy *et al.*, 2003; Friedman *et al.*, 2002). A recent study reported that the growth rates of *Listeria monocytogenes* strains observed at 15 °C and at 5 °C were significantly reduced by treatment with 1% and 2% clove oil (Mytle *et al.*, 2006) and furthermore, Ogunwande *et al.* (2005) found that the essential oil of the fruit exhibited strong antibacterial activity against *Staphylococcus aureus*, while the leaf oil strongly inhibited the growth of *Bacillus cereus*, with an MIC of 39 μ g/mL.

In view of the fact that coagulase-negative Staphylococci (CoNS) represent a hazard to hospital patients with poor immune responses and have the ability to survive a long time on medical devices (Neely and Maley, 2000), it was decided to investigate the activity on a large number of multi-resistant *Staphylococcus epidermidis*. Characterized clove oil was therefore screened against 32 multi-resistant *Staphylococcus epidermidis* strains (Table 2) isolated from dialysis biomaterial using an agar disk diffusion assay as described previously (Perez *et al.*, 1999; Bagamboula *et al.*, 2004). Each bacterial strain demonstrated a significant degree of sensitivity to the clove essential oil, and extensive activity against

Table 2. Antibacterial activity of essential oil of clove buds against 32 *S. epidermidis* strains and eight human pathogenic bacteria

Bacterial strains	Oxa ^a	Number of resistance	Diameter of inhibition (mm)	SD ^b	Antibacterial activity ^c	Gent ^d
<i>S. epidermidis</i> S15	R	10	13.33	0.57	(++)	17
S9	S	5	13.33	0.57	(++)	29
E5	S	1	13.66	0.57	(++)	30
S43	S	4	12.33	0.57	(++)	28
S16	S	3	12	0	(++)	31
S26	R	13	11	0	(++)	20
S40	R	8	11.66	0.57	(++)	23
E21	S	2	12	0	(++)	25
S48	R	8	12.66	0.57	(++)	22
E24	S	4	12	0	(++)	24
S22	S	4	12.66	0.57	(++)	26
E15	R	12	12.33	0.57	(++)	22
E11	R	6	11.33	0.57	(++)	23
E7	S	8	11.66	0.57	(++)	28
S33	S	5	13.66	0.57	(++)	33
E6	S	3	11.66	0.57	(++)	25
E4	R	9	12.66	0.57	(++)	27
S35	S	1	11.33	0.57	(++)	21
S2	S	3	10.33	0.57	(+)	25
E18	S	5	11.66	0.57	(++)	30
S59	S	4	14.66	0.57	(++)	24
S56	R	2	10	0	(+)	23
E9	S	6	13	1	(++)	23
S21	R	4	13.33	0.57	(++)	29
E10	S	1	14	1	(++)	29
E13	R	8	15.66	0.57	(+++)	31
E20	R	6	15	1	(++)	30
S25	S	5	13.33	0.57	(++)	31
S27	R	14	16.66	0.57	(+++)	33
S23	S	6	19.66	0.57	(+++)	36
S38	S	2	15.33	0.57	(+++)	34
S12	S	8	14.33	0.57	(++)	29
<i>S. epidermidis</i> CIP106510	^e ND	ND	16.33	0.57	(+++)	22
<i>S. aureus</i> ATCC25923	ND	ND	14.66	1.15	(++)	33
<i>E. coli</i> ATCC 35218	ND	ND	13.66	0.57	(++)	26
<i>L. monocytogenes</i> ATCC19115	ND	ND	15	0	(++)	38
<i>E. faecalis</i> ATCC29212	ND	ND	11	0	(++)	26
<i>P. aeruginosa</i> ATCC 27853	ND	ND	9	0	(+)	30
<i>Micrococcus luteus</i> NCIMB 8166	ND	ND	12.33	0.57	(++)	26
<i>Salmonella typhimurium</i> LT2	ND	ND	15.66	0.57	(++)	20

^a Oxacilline; ^b SD, standard deviation; ^c (-) <8 mm; (+) 8–10 mm; (++) 11–15 mm; (+++) >16 mm; ^d Gent, gentamicin (500 µg); ^e ND, not determined.

Gram-positive bacteria, producing a clear zone of inhibition against the majority of the tested strains (Fig. 1). Furthermore, the highest level of activity was observed against five strains of *S. epidermidis* (reference strains *S. epidermidis* CIP106510, E13, S27, S23 and S38), with an inhibition zone of >16 mm (Table 2). The oil was also active against 26 strains of *S. epidermidis* isolated from dialysis fluids, three human pathogenic Grampositive cocci, two Gramnegative bacilli and one Grampositive bacillus (diameter of inhibition zone: 11–15 mm). In contrast, the oil was ineffective against *P. aeruginosa* ATCC 27853 (diameter of inhibition zone: 9 mm). These results are in agreement with those of another study reporting that clove essential oil exhibited antibacterial activity against a large number of methicillin-resistant *S. epidermidis* and *S. aureus* (Enzo and Susan, 2002). However, the oil also appears to be effective against both Gram-positive and Gram-negative microorganisms, contrasting with results found in other studies (Zaika, 1988; Smith-Palmer *et al.*, 1998).

Fungicidal activity

Natural compounds remain an interesting source of new antifungal metabolites. The phenolic components, carvacrol and eugenol, are known to possess fungicidal characteristics (Manohar *et al.*, 2001), including activity against fungi isolated from onychomycosis (Gayoso *et al.*, 2005). The main antifungal action appears to be exerted on the cellular membrane (Cox *et al.*, 2001). Eugenol has shown antifungal activity against *Candida albicans* and *Trichophyton mentagrophytes* (Tampieri *et al.*, 2005) and Núñez *et al.* (2001) demonstrated that the mixture of clove oleoresin with concentrated sugar solution produced a strong fungicidal effect by reducing fungi inoculum size. In a recent report, SEM micrographs showed significant morphological damage with cellular deformity to *Saccharomyces cerevisiae* cells by clove oil (Chami *et al.*, 2005). The fungicidal activity of *E. caryophyllata* essential oil has also been reported on several food-borne fungal species (Velluti *et al.*, 2004;




Figure 1. Effect of clove oil on bacterial growth. Bacterial strains were seeded on Muller Hinton infusion agar. Paper disks containing 10 mg of clove oil or gentamicin (500 µg) were placed onto the seeded agar. Disks without clove oil or antibiotics were used as negative controls. The cultures were incubated for 24 h at 37 °C, and the inhibition zone diameter was measured. (A) *S. epidermidis* CIP106510; (B) *S. aureus* ATCC 25923; (C) *E. coli* ATCC 35218; (D) *P. aeruginosa* ATCC 27853.

Lopez *et al.*, 2005) and it was observed in a recent study that the essential oil of clove even inhibited the growth of *Aspergillus niger* (Pawar and Thaker, 2006).

Antiviral activity

Generally speaking, viruses are highly sensitive to the components of essential oils, and phenylpropanoids, monoterpenols and monoterpenals have shown *in vitro* antiviral activity. Hussein *et al.* (2000) found that *Syzygium aromaticum* extract was highly active at inhibiting replication of the hepatitis C virus (≥90% inhibition at 100 µg/mL). Kurokawa *et al.* (1998) isolated and identified an anti-HSV compound, eugenin, from the extracts of *Syzygium aromaticum*, which showed specificity in inhibiting HSV-1 DNA polymerase activity.

Antioxidant capacity

Many natural antioxidants are plant phenolics found in every part of the plant, including the fruit, seeds and leaves (Kim *et al.*, 1997). The major constituent of clove oil is eugenol, to which are attributed many of the antioxidant properties (Ogata *et al.*, 2000). The antioxidant activity may occur via various mechanisms such as scavenging the radicals and chelating metal ions. Eugenol reportedly participates in photochemical reactions (Mihara and Shibamoto, 1982), and displays strong antioxidant activity (Ogata *et al.*, 2000) and photocytotoxicity (Atsumi *et al.*, 2001). Jirovetz *et al.* (2006) found that the antioxidant action of 0.005% clove oil was identical to that of standard butylated hydroxytoluene at a concentration of 0.01%. It manifests considerable chelating potential against Fe³⁺, resulting in the prevention of the initiation of hydroxyl radicals (Jirovetz *et al.*, 2006). Clove oil thus

shows powerful antioxidant activity; moreover, it can be used as an easily accessible source of natural antioxidants and in pharmaceutical applications (Gülçin *et al.*, 2004).

Antitumor activity

Clove essential oil has been reported to show anti-carcinogenic (Zheng *et al.*, 1992) and antimutagenic potential (Miyazawa and Hisama, 2001). Volatile oils display cytotoxic action towards the human tumor cell lines PC-3 and Hep G2 (Ogunwande *et al.*, 2005; Yoo *et al.*, 2005) and in a recent study, eugenol was shown to induce apoptosis of human cancer cells (Namiki, 1994) with the major antimutagenic compound being identified as dehydrodieugenol. More recently, the antimutagenic activity of cinnamaldehyde was reported in human-derived hepatoma cells, where it suppressed the frequency of micronuclei induced by various heterocyclic amines (Sanyal *et al.*, 1997). Ohta *et al.* (1983) suggested that cinnamaldehyde reduced UV-induced mutagenesis, as well as mutagenesis induced by furylfuramide (AF-2) in *E. coli* WP2s.

Anaesthetic activity

Eugenol is used in a wide range of applications, such as a local anaesthetic in dentistry and as an ingredient in dental cement for temporary fillings (Markowitz *et al.*, 1992). It is relatively user-friendly and can be used in lower concentrations than other local anaesthetics (Keene *et al.*, 1998) and it is rapidly metabolized and excreted, thus requiring no withdrawal period (Wagner *et al.*, 2002). It has been shown to be effective in anaesthetizing fish such as rainbow trout, *Oncorhynchus mykiss* Walbaum (Anderson *et al.*, 1997; Keene *et al.*, 1998) and channel catfish (Waterstrat,

1999). Eugenol at 65 mg/L was shown to be safely and effectively induce all stages of anaesthesia in juvenile and sub-adult tambaqui fish within the desired time. Further research needs to focus on assessing its efficacy in other tropical species, as well as investigating its lethal dosage (Roubach *et al.*, 2005).

Insecticidal activity

The use of drugs to control parasitic arthropods presents several challenges, including drug resistance and environmental damage (O'Brien, 1999). The biological activity of *Eugenia caryophyllata* oil has been investigated against several parasites. It was shown to inhibit the emergence of *Culex pipiens* larvae (El Hag *et al.*, 1999) and to display insecticidal activity against *Pediculus capitis* (Yang *et al.*, 2003), *Anopheles dirus* mosquitoes (Trongtokit *et al.*, 2005) and some stored product insects and suppresses progeny development of *Tribolium castaneum* and *Sitophilus zeamais* with isoeugenol being particularly active (Ho *et al.*, 1994). Clove essential oil has also showed acaricidal activity towards *Dermatophagoides farinae* and *D. pteronyssinus* with eugenol being identified as the acaricidal constituent of the oil. Eugenol congeners also exhibited potent acaricidal activity against both mite species (Kim *et al.*, 2003), and Perrucci *et al.* (1995) reported its effects against the causative organism of psoroptic mange, *Psoroptes cuniculi*, by direct contact and by contact only with the vapour phase. A more recent study has confirmed that clove oil could be used as a novel fumigant against Japanese termites (Park and Shin, 2005).

CONCLUSIONS

This review describes the known effects of clove oil and additional work has clarified its chemical composition by GC-MS and enabled the identification of 36 components. The highest concentration was, as expected, of eugenol (88.58%), but the second most abundant compound was eugenyl acetate (5.62%), followed by β -caryophyllene (1.38%). In view of the known activities of the constituents and the variability of the oil, it is important that the composition is known.

It has been shown that clove oil possesses significant antioxidant properties and shows potential as a natural preservative or as a source of natural antioxidants for use in pharmaceutical applications. It induced apoptosis of human cancer cells and is considered to be an effective guard against virus infection when used as an antiseptic. The highest antibacterial activity of the essential oil was observed against five strains of *S. epidermidis* (reference strains CIP106510, E13, S27, S23 and S38) and is thought to be due mainly to the presence of eugenol. In addition, this oil was active against 26 *S. epidermidis* isolated from a dialysis fluid, three human pathogenic Grampositive cocci, two Gramnegative bacilli and one Grampositive bacillus.

In terms of a practical use of *Eugenia* oil-derived materials as novel insecticidal applications, further research is necessary to address the safety issues pertaining to human health as well as formulations for improving insecticidal potency and stability. Clove oil is non-toxic to fish, and acts as an anaesthetic for some fish species, but the toxicity to other animals is not known.

REFERENCES

- Agvald-Ohman C, Wernerman J, Nord CE, Edlund C. 2003. Anaerobic bacteria commonly colonize the lower airways of intubated ICU patients. *Clin Microbiol Infect* **9**: 397–405.
- Anderson GW, McKinley SR, Colavecchia M. 1997. The use of clove oil as an anaesthetic for rainbow trout and its effects on swimming performance. *North Am J Fish Management* **17**: 301–307.
- Atsumi T, Iwakura I, Fujisawa S, Ueha T. 2001. Reactive oxygen species generation and photo-cytotoxicity of eugenol in solutions of various pH. *Biomaterials* **22**: 1459–1466.
- Bagamboula CF, Uyttendaele M, Debevere J. 2004. Inhibitory effect of thyme and basil essential oils, carvacrol, thymol, estragol, linalool and p-cymene towards *Shigella sonnei* and *S. flexneri*. *Food Microbiol* **21**: 33–42.
- Beuchat LR. 2000. Control of foodborne pathogens and spoilage microorganisms by naturally occurring antimicrobials. In *Microbial Food Contamination*, Wilson CL, Droby S (eds). CRC Press: Boca Raton, FL, 149–169.
- Burt SA, Reinders RD. 2003. Antibacterial activity of selected plant essential oils against *Escherichia coli* O157:H7. *Lett Appl Microbiol* **36**: 162–167.
- Cai L, Wu CD. 1996. Compounds from *Syzygium aromaticum* possessing growth inhibitory activity against oral pathogens. *J Nat Prod* **59**: 987–990.
- Chami F, Chami N, Bennis S, Bouchikhi T, Remmal A. 2005. Oregano and clove essential oils induce surface alteration of *Saccharomyces cerevisiae*. *Phytother Res* **19**: 405–408.
- Cox SD, Mann CM, Markham JL. 2001. Interactions between components of the essential oil of *Melaleuca alternifolia*. *J Appl Microbiol* **91**: 492–497.
- Cressy HK, Jerrett AR, Osborne CM, Bremer PJ. 2003. A novel method for the reduction of numbers of *Listeria monocytogenes* cells by freezing in combination with an essential oil in bacteriological media. *J Food Protect* **66**: 390–395.
- El Hag EA, El Nadi AH, Zaiton AA. 1999. Toxic and growth retarding effects of three plant extracts on *Culex pipiens* larvae (Diptera: Culicidae). *Phytother Res* **13**: 388–392.
- Enzo AP, Susan JS. 2002. Antibacterial activity of Australian plant extracts against methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant enterococci (VRE). *J Basic Microbiol* **42**: 444–448.
- Feres M, Figueiredo LC, Barreto IM, Coelho MN, Araujo MW, Cortelli SC. 2005. *In vitro* antimicrobial activity of plant extracts and propolis in saliva samples of healthy and periodontally-involved subjects. *J Int Acad Periodontol* **7**: 90–96.
- Friedman M, Henika PR, Mandrell RE. 2002. Bactericidal activities of plant essential oils and some of their isolated constituents against *Campylobacter jejuni*, *Escherichia coli*, *Listeria monocytogenes*, and *Salmonella enterica*. *J Food Prot* **65**: 1545–1560.
- Gayoso CW, Lima EO, Olivera VT *et al.* 2005. Sensitivity of fungi isolated from onychomycosis to *Eugenia caryophyllata* essential oil and eugenol. *Fitoterapia* **76**: 247–249.
- Gülçin İ, Güngör İ, Beydemir SS, Elmastaş M, Küfrevioğlu I. 2004. Comparison of antioxidant activity of clove (*Eugenia caryophyllata* Thunb) buds and lavender (*Lavandula stoechas* L.). *Food Chem* **87**: 393–400.
- Ho SH, Cheng LPL, Sim KY, Tan HTW. 1994. Potential of cloves (*Syzygium aromaticum* (L.) Merr. and Perry as a grain protectant against *Tribolium castaneum* (Herbst) and *Sitophilus zeamais* Motsch. *Posthar Vest Biol Technol* **4**: 179–183.
- Huebner J, Goldmann DA. 1999. Coagulase-negative staphylococci: role as pathogens. *Annu Rev Med* **50**: 223–236.

- Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno K. 2000. Inhibitory effects of Sudanese medical plant extracts on hepatitis C virus (HCV) protease. *Phytother Res* **14**: 510–516.
- Jirovetz L, Buchbauer G, Stoilova I, Stoyanova A, Krastanov A, Schmidt E. 2006. Chemical composition and antioxidant properties of clove leaf essential oil. *J Agric Food Chem* **54**: 6303–6307.
- Kalemba D, Kunicka A. 2003. Antibacterial and antifungal properties of essential oils. *Curr Med Chem* **10**: 813–829.
- Keene JL, Noakes DLG, Moccia RD, Soto CG. 1998. The efficacy of clove oil as an anaesthetic for rainbow trout, *Oncorhynchus mykiss* (Walbaum). *Aquacult Res* **29**: 89–101.
- Kim EH, Kim HK, Ahn YJ. 2003. Acaricidal activity of clove bud oil compounds against *Dermatophagoides farinae* and *Dermatophagoides pteronyssinus* (Acari: Pyroglyphidae). *J Agric Food Chem* **51**: 885–889.
- Kim B, Kim J, Kim H, Heo M. 1997. Biological screening of 100 plants for cosmetic use. II. Antioxidative activity and free radical scavenging activity. *Int J Cosmet Sci* **19**: 299–307.
- Kim HM, Lee EH, Hong SH *et al.* 1998. Effect of *Syzygium aromaticum* extract on immediate hypersensitivity in rats. *J Ethnopharmacol* **60**: 125–131.
- Kurokawa M, Hozumi T, Basnet P *et al.* 1998. Purification and characterization of eugenin as an anti-herpesvirus compound from *Geum japonicum* and *Syzygium aromaticum*. *J Pharmacol Exp Ther* **284**: 728–735.
- Larhsini M, Oumouid L, Lazrek HB *et al.* 2001. Antibacterial activity of some Moroccan medicinal plants. *Phytother Res* **15**: 250–252.
- Lee KG, Shibamoto T. 2002. Antioxidant property of aroma extract isolated from clove buds (*Syzygium aromaticum* (L.) Merr. Et Perry). *Food Chem* **74**: 443–448.
- Lopez P, Sanchez C, Batlle R, Nerin C. 2005. Solid- and vapor-phase antimicrobial activities of six essential oils: susceptibility of selected foodborne bacterial and fungal strains. *J Agric Food Chem* **53**: 6939–6946.
- Manohar V, Ingram C, Gray J *et al.* 2001. Antifungal activities of organon oil against *Candida albicans*. *Mol Cel Biochem* **228**: 111–117.
- Markowitz K, Moynihan M, Liu M, Kim S. 1992. Biologic properties of eugenol and zinc oxide-eugenol. A clinically oriented review. *Oral Surg Oral Med Oral Pathol* **73**: 729–737.
- Mihara S, Shibamoto T. 1982. Photochemical reactions of eugenol and related compounds: Synthesis of new flavor chemicals. *J Agric Food Chem* **30**: 1215–1218.
- Miyazawa M, Hisama M. 2001. Suppression of chemical mutagen induced SOS response by alkylphenols from clove (*Syzygium aromaticum*) in *Salmonella typhimurium* TA1535/pSK1002 umu test. *J Agric Food Chem* **49**: 4019–4025.
- Mytle N, Anderson GL, Doyle MP, Smith MA. 2006. Antimicrobial activity of clove (*Syzygium aromaticum*) oil in inhibiting *Listeria monocytogenes* on chicken frankfurters. *Food Control* **17**: 102–107.
- Namiki M. 1994. Antimutagen and anticarcinogen research in Japan. In *Food Phytochemicals for Cancer Prevention III*, Huang M-T, Osawa T, Ho C-T, Rosen RT (eds). Maple Press: York, Vol. 546, 64–81.
- Neely AN, Maley MP. 2000. Survival of enterococci and staphylococci on hospital fabrics and plastic. *J Clin Microbiol* **38**: 724–726.
- Núñez L, D'Aquino M, Chirife J. 2001. Antifungal properties of clove oil (*Eugenia caryophyllata*) in sugar solution. *Braz J Microbiol* **32**: 123–126.
- O'Brien DJ. 1999. Treatment of psoroptic mange with reference to epidemiology and history. *Veter Parasitol* **83**: 177–185.
- Ogata M, Hoshi M, Urano S, Endo T. 2000. Antioxidant activity of eugenol and related monomeric and dimeric compounds. *Chem Pharm Bull* **48**: 1467–1469.
- Ogunwande IA, Olawore NO, Ekundayo O, Walker TM, Schmidt JM, Setzer WN. 2005. Studies on the essential oils composition, antibacterial and cytotoxicity of *Eugenia uniflora* L. *Int J Aromather* **15**: 147–152.
- Ohta T, Watanabe K, Moriya M, Shirasu Y, Kada T. 1983. Antimutagenic effects of cinnamaldehyde on chemical mutagenesis in *Escherichia coli*. *Mutat Res* **107**: 219–227.
- Park IK, Lee HS, Lee SG, Park JD, Ahn YJ. 2000. Insecticidal and fumigant activities of *Cinnamomum cassia* bark-derived materials against *Mechoris ursulus* (Coleoptera: Atteblabidae). *J Agric Food Chem* **48**: 2528–2531.
- Park IK, Shin SC. 2005. Fumigant activity of plant essential oils and components from garlic (*Allium sativum*) and clove bud (*Eugenia caryophyllata*) oils against the Japanese termite (*Reticulitermes speratus*). *J Agric Food Chem* **53**: 4388–4392.
- Pawar VC, Thaker VS. 2006. *In vitro* efficacy of 75 essential oils against *Aspergillus niger*. *Mycoses* **49**: 316–323.
- Perez C, Agnese AM, Cabrera JL. 1999. The essential oil of *Senecio graveolens* (Compositae): chemical composition and antimicrobial activity tests. *J Ethnopharmacol* **66**: 91–96.
- Perrucci S, Macchioni G, Cioni PL, Flamini G, Morelli I. 1995. Structure/activity relationship of some natural monoterpenes as acaricides against *Psoroptes cuniculi*. *J Nat Prod* **8**: 1261–1264.
- Prashar A, Locke IC, Evans CS. 2006. Cytotoxicity of clove (*Syzygium aromaticum*) oil and its major components to human skin cells. *Cell Prolif* **39**: 241–248.
- Roubach R, Gomes LC, Leao Fonseca FA, LuizVal A. 2005. Eugenol as an efficacious anaesthetic for tambaqui, *Colossoma macropomum* (Cuvier). *Aquacult Res* **36**: 1056–1061.
- Sanyal R, Darroudi F, Parzefall W, Nagao M, Knasmuller S. 1997. Inhibition of the genotoxic effects of heterocyclic amines in human derived hepatoma cells by dietary antimutagens. *Mutagenesis* **12**: 297–303.
- Smith-Palmer A, Stewart J, Fyfe L. 1998. Antimicrobial properties of plant essential oils and essences against five important food-borne pathogens. *Lett Appl Microbiol* **26**: 118–122.
- Tampieri MP, Galuppi R, Macchioni F *et al.* 2005. The inhibition of *Candida albicans* by selected essential oils and their major components. *Mycopathologia* **159**: 339–345.
- Trongtokit Y, Rongsriyam Y, Komalamisra N, Apiwathasorn C. 2005. Comparative repellency of 38 essential oils against mosquito bites. *Phytother Res* **19**: 303–309.
- Velluti A, Sanchis V, Ramos AJ, Turon C, Marin S. 2004. Impact of essential oil on growth rate, zearalenone and deoxynivalenol production by *Fusarium graminearum* under different temperature and water activity condition in maize grain. *J Appl Microbiol* **96**: 716–724.
- Wagner E, Arndt R, Hilton B. 2002. Physiological stress responses, egg survival and sperm motility of rainbow trout broodstock anesthetized with clove oil, tricaine methanesulfonate or carbon dioxide. *Aquaculture* **211**: 353–366.
- Waterstrat PR. 1999. Induction and recovery from anaesthesia in channel catfish *Ictalurus punctatus* fingerlings exposed to clove oil. *J World Aquacult Soc* **30**: 250–255.
- Yang YC, Lee SH, Lee WJ, Choi DH, Ahn YJ. 2003. Ovicidal and adulticidal effects of *Eugenia caryophyllata* bud and leaf oil compounds on *Pediculus capitis*. *J Agric Food Chem* **51**: 4884–4888.
- Yoo CB, Han KT, Cho KS *et al.* 2005. Eugenol isolated from the essential oil of *Eugenia caryophyllata* induces a reactive oxygen species-mediated apoptosis in HL-60 human promyelocytic leukemia cells. *Cancer Lett* **225**: 41–52.
- Zaika LL. 1988. Spices and herbs: their antimicrobial activity and its determination. *J Food Nutr* **9**: 97–118.
- Zheng GQ, Kenney PM, Lam LKT. 1992. Sesquiterpenes from clove (*Eugenia caryophyllata*). *J Nat Prod* **55**: 999–1003.